In contrast to experimental cholestasis, where a treatment usually elicits a more homogenous response, it is known that human cholestasis varies greatly in response to UDCA, FGF19 analog, or ASBT inhibitor treatment (15, 16, 22). This evidence concerns the gene FGF19 and cholestasis.